bersanlimab

Bersanlimab is a fully human investigational monoclonal antibody that targets intercellular adhesion molecule 1 (ICAM-1 or CD54). It is designed to bind specifically to ICAM-1 on the surface of cells. The drug exerts its anticancer effects through mechanisms including antagonism of ICAM-1 function, stimulation of apoptosis in target cells, and induction of antibody-dependent cell cytotoxicity. Bersanlimab was primarily developed for the treatment of multiple myeloma and has demonstrated activity in preclinical models by reducing tumor growth and prolonging survival. It was granted orphan drug status for multiple myeloma but development has been discontinued for this indication[1][2][7].

Other names

anti-icam-1 monoclonal antibody bi-505anti-icam1 monoclonal antibody bi-505anti-icam 1 monoclonal antibody bi-505immunoglobulin g1-lambda anti-(homo sapiens icam1(intercellular adhesion molecule 1, icam-1, cd54)) human monoclonal antibody